Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
25
10
2023
accepted:
27
06
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Booster vaccinations are recommended to improve protection against severe disease from SARS-CoV-2 infection. With primary vaccinations involving various adenoviral vector and mRNA-based formulations, it remains unclear if these differentially affect the immune response to booster doses. We examined the effects of homologous (mRNA/mRNA) and heterologous (adenoviral vector/mRNA) vaccination on antibody and memory B cell (Bmem) responses against ancestral and Omicron subvariants. Healthy adults who received primary BNT162b2 (mRNA) or ChAdOx1 (vector) vaccination were sampled 1-month and 6-months after their 2nd and 3rd dose (homologous or heterologous) vaccination. Recombinant spike receptor-binding domain (RBD) proteins from ancestral, Omicron BA.2 and BA.5 variants were produced for ELISA-based serology, and tetramerized for immunophenotyping of RBD-specific Bmem. Dose 3 boosters significantly increased ancestral RBD-specific plasma IgG and Bmem in both cohorts. Up to 80% of ancestral RBD-specific Bmem expressed IgG1
Identifiants
pubmed: 39013889
doi: 10.1038/s41541-024-00919-8
pii: 10.1038/s41541-024-00919-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129Informations de copyright
© 2024. The Author(s).
Références
World Health Organisation. WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int/ (2023).
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
pubmed: 32702298
pmcid: 7445431
doi: 10.1016/S0140-6736(20)31604-4
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
pubmed: 33306989
pmcid: 7723445
doi: 10.1016/S0140-6736(20)32661-1
Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).
pubmed: 33882225
doi: 10.1056/NEJMoa2101544
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
pubmed: 34002089
doi: 10.1038/s41591-021-01377-8
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E. & van Zelm, M. C. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochem Soc. Trans. 50, 1643–1658 (2022).
pubmed: 36421662
pmcid: 9788580
doi: 10.1042/BST20220415
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
pubmed: 32015508
pmcid: 7094943
doi: 10.1038/s41586-020-2008-3
Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).
pubmed: 34648302
pmcid: 9284784
doi: 10.1126/science.abm0829
Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572–577 (2021).
pubmed: 34044428
doi: 10.1038/s41586-021-03653-6
Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979–1993 (2021).
pubmed: 33220855
doi: 10.1016/S0140-6736(20)32466-1
Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout-Full data and analysis, https://www.health.gov.au/resources/collections/covid-19-vaccine-rollout-full-data-and-analysis (2023).
Greinacher, A. et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med 384, 2092–2101 (2021).
pubmed: 33835769
doi: 10.1056/NEJMoa2104840
Pavord, S. et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med 385, 1680–1689 (2021).
pubmed: 34379914
doi: 10.1056/NEJMoa2109908
Fryer, H. A. et al. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants. J. Clin. Immunol. 43, 1506–1518 (2023).
pubmed: 37322095
pmcid: 10499924
doi: 10.1007/s10875-023-01527-2
Australian Government Department of Health. Coronavirus (COVID-19) case numbers and statistics, https://www.health.gov.au/health-alerts/covid-19/case-numbers-and-statistics?language=und
Hartley, G. E. et al. The second COVID-19 mRNA vaccine dose enhances the capacity of Spike-specific memory B cells to bind Omicron BA.2. Allergy 78, 855–858 (2023).
pubmed: 36541822
doi: 10.1111/all.15624
Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).
pubmed: 33858945
pmcid: 8158969
doi: 10.1126/sciimmunol.abi6950
Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141–145 (2022).
pubmed: 35168246
pmcid: 9204750
doi: 10.1038/s41586-022-04527-1
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).
pubmed: 34182569
pmcid: 8935394
doi: 10.1038/s41586-021-03738-2
Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517–522 (2021).
pubmed: 34619745
pmcid: 8674133
doi: 10.1038/s41586-021-04060-7
Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603–613.e615 (2022).
pubmed: 35026152
doi: 10.1016/j.cell.2021.12.026
Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434–2451.e2417 (2022).
pubmed: 35764089
pmcid: 9135677
doi: 10.1016/j.cell.2022.05.022
Cho, A. et al. Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. J. Exp. Med. 219, e20220732 (2022).
pubmed: 35776090
pmcid: 9253517
doi: 10.1084/jem.20220732
Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 185, 1875–1887.e1878 (2022).
pubmed: 35523182
pmcid: 8989683
doi: 10.1016/j.cell.2022.04.009
Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466.e454 (2022).
pubmed: 34995482
pmcid: 8733787
doi: 10.1016/j.cell.2021.12.033
GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 7, eabo2202 (2022).
pubmed: 35113647
doi: 10.1126/sciimmunol.abo2202
Haveri, A. et al. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Eur. J. Immunol. 52, 816–824 (2022).
pubmed: 35312186
pmcid: 9087434
doi: 10.1002/eji.202149785
Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8, eade2798 (2023).
pubmed: 36548397
doi: 10.1126/sciimmunol.ade2798
de Jong, B. G. et al. Human IgG2- and IgG4-expressing memory B cells display enhanced molecular and phenotypic signs of maturity and accumulate with age. Immunol. Cell Biol. 95, 744–752 (2017).
pubmed: 28546550
pmcid: 5636940
doi: 10.1038/icb.2017.43
Hartley, G. E. et al. Influenza-specific IgG1(+) memory B-cell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clin. Transl. Immunol. 9, e1199 (2020).
doi: 10.1002/cti2.1199
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020).
pubmed: 32555388
pmcid: 7442695
doi: 10.1038/s41586-020-2456-9
Suthar, M. S. et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep. Med. 1, 100040 (2020).
pubmed: 32835303
pmcid: 7276302
doi: 10.1016/j.xcrm.2020.100040
Hartley, G. E. et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 5, eabf8891 (2020).
pubmed: 33443036
pmcid: 7877496
doi: 10.1126/sciimmunol.abf8891
Jennifer, B. et al. Transferrin receptor 1 is a cellular receptor for human heme-albumin. Commun. Biol. 3, 621 (2020).
pubmed: 33110194
pmcid: 7591885
doi: 10.1038/s42003-020-01294-5
Ni, S., Yuan, Y., Kuang, Y. & Li, X. Iron Metabolism and Immune Regulation. Front Immunol. 13, 816282 (2022).
pubmed: 35401569
pmcid: 8983924
doi: 10.3389/fimmu.2022.816282
Ellebedy, A. H. et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat. Immunol. 17, 1226–1234 (2016).
pubmed: 27525369
pmcid: 5054979
doi: 10.1038/ni.3533
Andrews, S. F. et al. Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity 51, 398–410.e395 (2019).
pubmed: 31350180
doi: 10.1016/j.immuni.2019.06.024
Berkowska, M. A. et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 118, 2150–2158 (2011).
pubmed: 21690558
pmcid: 3342861
doi: 10.1182/blood-2011-04-345579
Berkowska, M. A. et al. Circulating Human CD27-IgA+ Memory B Cells Recognize Bacteria with Polyreactive Igs. J. Immunol. 195, 1417–1426 (2015).
pubmed: 26150533
doi: 10.4049/jimmunol.1402708
Buhre, J. S. et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front Immunol. 13, 1020844 (2022).
pubmed: 36713457
doi: 10.3389/fimmu.2022.1020844
Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924–944 (2022).
pubmed: 35202601
pmcid: 8863502
doi: 10.1016/S0140-6736(22)00152-0
Menni, C. et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 22, 1002–1010 (2022).
pubmed: 35405090
pmcid: 8993156
doi: 10.1016/S1473-3099(22)00146-3
Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C. & Boadu, E. F. Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Arch. Pub. Health 80, 200 (2022).
doi: 10.1186/s13690-022-00935-x
Dadras, O. et al. COVID-19 Vaccines’ Protection Over Time and the Need for Booster Doses; a Systematic Review. Arch. Acad. Emerg. Med 10, e53 (2022).
pubmed: 36033989
pmcid: 9397599
Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128–134 (2022).
pubmed: 35447027
pmcid: 9259484
doi: 10.1038/s41586-022-04778-y
Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).
pubmed: 35046572
pmcid: 8767537
doi: 10.1038/s41591-021-01676-0
Hvidt, A. K. et al. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Front Med (Lausanne) 9, 994160 (2022).
pubmed: 36262278
doi: 10.3389/fmed.2022.994160
Kaku, C. I. et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Science 375, 1041–1047 (2022).
pubmed: 35143256
doi: 10.1126/science.abn2688
Quandt, J. et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci. Immunol. 7, eabq2427 (2022).
pubmed: 35653438
doi: 10.1126/sciimmunol.abq2427
Zurbuchen, Y. et al. Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2. Nat. Immunol. 24, 955–965 (2023).
pubmed: 37106039
pmcid: 10232369
doi: 10.1038/s41590-023-01497-y
Lau, D. et al. Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation. Sci. Immunol. 2, eaai8153 (2017).
pubmed: 28783670
pmcid: 5896567
doi: 10.1126/sciimmunol.aai8153
Jenks, S. A. et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity 49, 725–739.e726 (2018).
pubmed: 30314758
pmcid: 6217820
doi: 10.1016/j.immuni.2018.08.015
Matz, H. C., McIntire, K. M. & Ellebedy, A. H. Persistent germinal center responses: slow-growing trees bear the best fruits. Curr. Opin. Immunol. 83, 102332 (2023).
pubmed: 37150126
pmcid: 10829534
doi: 10.1016/j.coi.2023.102332
Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7–18 (2022).
pubmed: 34873279
doi: 10.1038/s41577-021-00657-1
Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol. 67, 171–182 (2015).
pubmed: 25900877
doi: 10.1016/j.molimm.2015.03.255
Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 5, 520 (2014).
pubmed: 25368619
pmcid: 4202688
doi: 10.3389/fimmu.2014.00520
Chung, A. W. et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med 6, 228ra238 (2014).
doi: 10.1126/scitranslmed.3007736
Dobaño, C. et al. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children. Clin. Vaccin Immunol. 19, 157–166 (2012).
doi: 10.1128/CVI.05523-11
Hendrikx, L. H. et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 29, 6874–6880 (2011).
pubmed: 21803088
doi: 10.1016/j.vaccine.2011.07.055
Heeringa, J. J. et al. Induction of IgG(2) and IgG(4) B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy 75, 1121–1132 (2020).
pubmed: 31587307
doi: 10.1111/all.14073
McKenzie, C. I. et al. RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect. Allergy 78, 822–835 (2023).
pubmed: 36153670
doi: 10.1111/all.15529
Wilson, B. & Geetha, K. M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 74, 103553 (2022).
pubmed: 35783677
pmcid: 9238147
doi: 10.1016/j.jddst.2022.103553
Kalkeri, R. et al. Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines. J. Infect. 88, 106119 (2024).
pubmed: 38360356
doi: 10.1016/j.jinf.2024.106119
Pillai, S. Is it bad, is it good, or is IgG4 just misunderstood? Sci. Immunol. 8, eadg7327 (2023).
pubmed: 36749191
doi: 10.1126/sciimmunol.adg7327
Munemura, R. et al. Distinct disease-specific Tfh cell populations in 2 different fibrotic diseases: IgG(4)-related disease and Kimura disease. J. Allergy Clin. Immunol. 150, 440–455.e417 (2022).
pubmed: 35568079
pmcid: 10369367
doi: 10.1016/j.jaci.2022.03.034
Terreri, S. et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe 30, 400–408.e404 (2022).
pubmed: 35134333
pmcid: 8820949
doi: 10.1016/j.chom.2022.01.003
Bates, T. A. et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci. Immunol. 7, eabn8014 (2022).
pubmed: 35076258
doi: 10.1126/sciimmunol.abn8014
Akkaya, M., Kwak, K. & Pierce, S. K. B cell memory: building two walls of protection against pathogens. Nat. Rev. Immunol. 20, 229–238 (2020).
pubmed: 31836872
doi: 10.1038/s41577-019-0244-2
Edwards, E. S. J. et al. Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells. Front Immunol. 10, 2593 (2019).
pubmed: 31803177
pmcid: 6873234
doi: 10.3389/fimmu.2019.02593
Aggarwal, A. et al. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nat. Microbiol 7, 896–908 (2022).
pubmed: 35637329
pmcid: 9159941
doi: 10.1038/s41564-022-01135-7
Akerman, A. et al. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine 90, 104545 (2023).
pubmed: 37002990
pmcid: 10060887
doi: 10.1016/j.ebiom.2023.104545
Kalina, T. et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986–2010 (2012).
pubmed: 22948490
pmcid: 3437409
doi: 10.1038/leu.2012.122